$357 Million is the total value of Eversept Partners, LP's 62 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
XENE | XENON PHARMACEUTICALS INC | $2,211,992 | -3.0% | 224,340 | 0.0% | 0.62% | -6.9% | |
AFMD | AFFIMED N V | $924,631 | -31.7% | 322,171 | 0.0% | 0.26% | -34.4% | |
EIGR | EIGER BIOPHARMACEUTICALS INC | $738,905 | -24.2% | 69,708 | 0.0% | 0.21% | -27.1% | |
DRNA | DICERNA PHARMACEUTICALS INC | $646,916 | +7.5% | 41,074 | 0.0% | 0.18% | +2.8% | |
ALBO | ALBIREO PHARMA INC | $581,255 | +0.1% | 18,029 | 0.0% | 0.16% | -3.6% | |
AQXP | AQUINOX PHARMACEUTICALS INC | $173,972 | -12.4% | 73,717 | 0.0% | 0.05% | -15.5% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2023-11-08
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
AMARIN CORP PLC | 21 | Q3 2023 | 12.5% |
DANAHER CORPORATION | 21 | Q3 2023 | 8.1% |
AFFIMED N V | 20 | Q3 2023 | 0.9% |
ARGENX SE | 19 | Q3 2023 | 2.0% |
GSK PLC | 18 | Q2 2022 | 13.1% |
ASCENDIS PHARMA A/S | 18 | Q1 2022 | 7.7% |
SANOFI | 18 | Q4 2022 | 7.2% |
ENSIGN GROUP INC | 18 | Q1 2022 | 8.6% |
CENTENE CORP DEL | 18 | Q3 2023 | 1.5% |
ZOGENIX INC | 17 | Q4 2021 | 12.4% |
View Eversept Partners, LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Cabaletta Bio, Inc. | February 14, 2023 | 282,874 | 1.0% |
Teligent, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
Teligent, Inc. | February 14, 2020 | 4,501,799 | 8.4% |
View Eversept Partners, LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR/A | 2023-11-08 |
13F-HR/A | 2023-11-08 |
13F-HR/A | 2023-11-08 |
13F-HR/A | 2023-11-08 |
13F-HR/A | 2023-11-08 |
13F-HR/A | 2023-11-08 |
View Eversept Partners, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.